Current limitations include: limited long-term safety data compared with established medicines trial populations that may not represent broader real-world groups evolving phase 3 research ongoing monitoring of adverse events the need for longer follow-up across different study populations This does not make the available data unimportant
Quick Summary: Most common thyroid conditions are compatible with GLP-1 medications
Foundayo is now the second GLP-1 medication to be approved in pill form
Its mechanism of action is unique
She adds that starting with a lower dose of 2 mg/week instead of 4 mg/week may help mitigate adverse effects
These people's metabolism have been completely shut off for their, much of their lives, you know, and obviously you have to weigh risk versus benefit with your clinician, your, you know, your practitioner, and I encourage everyone to do that